On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox. The writer is executive director of the Aspen Strategy Group and a visiting fellow at Stanford ...

Amid an ongoing pet food recall, the U.S. Food and Drug Administration (FDA) is urging pet owners not to give their dogs and cats certain food products from two different brands. Both the brands ...

and ANSWERS Straight Chicken Formula for Dogs “out of an abundance of caution,” according to the notice posted by the Food and Drug Administration (FDA). The samples that tested positive for ...